Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation — VITACTOH  

Liver Transplantation Clinical Trial

Official title: Intravenous Vitamin C for the Prevention of Postreperfusion Syndrome in Orthotopic Liver Transplantation From Deceased Donors

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in preventing the postreperfusion syndrome in liver transplantation. The main questions it aims to answer are:

• Can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation ?

• Can ascorbic acid decrease the incidence of liver graft dysfunction after liver transplantation?

• Can ascorbic acid decreased the incidence of postoperative complications after liver transplantation ?

Participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or 100 ml of saline alone, during the anhepatic phase of liver transplantation before reperfusion of the new graft.

Researchers will compared the incidence of postreperfusion syndrome in both groups.

Clinical Trial Description

Researches will compared:

• Incidence of postreperfusion syndrome in liver transplantation

• Changes in interleukin values and other inflammatory markers before and after transplantation

• Incidence of liver graft dysfunction between groups

• Incidence of acute renal failure and other complications between groups ;

Related Conditions & MeSH terms

• Ascorbic Acid
• Liver Transplantation
• Postreperfusion Syndrome
• Syndrome

• NCT number: NCT05754242
• Study type: Interventional
• Source: Hospital Universitario Ramon y Cajal
• Contact: Luis Gajate, MD PhD
• Phone: +34913368269
• Email: gajate.luis@gmail.com
• Status: Recruiting
• Phase: Phase 2
• Start date: November 17, 2020
• Completion date: July 30, 2023